261 related articles for article (PubMed ID: 31711481)
1. Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model.
Liou AT; Liao CC; Chou SF; Chang YS; Chang CS; Shih C
J Biomed Sci; 2019 Nov; 26(1):93. PubMed ID: 31711481
[TBL] [Abstract][Full Text] [Related]
2. Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model.
Xu Y; Ma S; Zhu L; Huang Z; Chen L; Xu Y; Yin H; Peng T; Wang Y
Antiviral Res; 2017 Jan; 137():67-75. PubMed ID: 27864074
[TBL] [Abstract][Full Text] [Related]
3. Enterovirus A71 Infection Activates Human Immune Responses and Induces Pathological Changes in Humanized Mice.
Ke Y; Liu WN; Her Z; Liu M; Tan SY; Tan YW; Chan XY; Fan Y; Huang EK; Chen H; En Chang KT; Chan JKY; Hann Chu JJ; Chen Q
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429352
[TBL] [Abstract][Full Text] [Related]
4. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
Tsai YH; Huang SW; Hsieh WS; Cheng CK; Chang CF; Wang YF; Wang JR
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996087
[TBL] [Abstract][Full Text] [Related]
5. A Polysaccharide Purified From
Lin YL; Shih C; Cheng PY; Chin CL; Liou AT; Lee PY; Chiang BL
Front Immunol; 2020; 11():561758. PubMed ID: 33117346
[TBL] [Abstract][Full Text] [Related]
6. Antivirals and vaccines for Enterovirus A71.
Lin JY; Kung YA; Shih SR
J Biomed Sci; 2019 Sep; 26(1):65. PubMed ID: 31481071
[TBL] [Abstract][Full Text] [Related]
7. Immunocompetent and Immunodeficient Mouse Models for Enterovirus 71 Pathogenesis and Therapy.
Shih C; Liao CC; Chang YS; Wu SY; Chang CS; Liou AT
Viruses; 2018 Nov; 10(12):. PubMed ID: 30487421
[TBL] [Abstract][Full Text] [Related]
8. [Analysis on epidemiological characteristics of enterovirus 71 cases of hand-foot-mouth disease based on the active monitoring in Guangdong Province in 2011-2015].
Xie DS; He JF; Yang F; Li H; Kang M; Zhang M; Ye X; Tan XH; Ni XH; Hu L; Sun LM
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):738-742. PubMed ID: 29996302
[No Abstract] [Full Text] [Related]
9. Immune responses against enterovirus A71 infection: Implications for vaccine success.
Aw-Yong KL; NikNadia NMN; Tan CW; Sam IC; Chan YF
Rev Med Virol; 2019 Sep; 29(5):e2073. PubMed ID: 31369184
[TBL] [Abstract][Full Text] [Related]
10. Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications.
Sun J; Yogarajah T; Lee RCH; Kaur P; Inoue M; Tan YW; Chu JJH
Sci Rep; 2020 May; 10(1):8159. PubMed ID: 32424333
[TBL] [Abstract][Full Text] [Related]
11. Interplays between Enterovirus A71 and the innate immune system.
Chen KR; Ling P
J Biomed Sci; 2019 Dec; 26(1):95. PubMed ID: 31787104
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Enterovirus A71 by a Novel 2-Phenyl-Benzimidazole Derivative.
Ibba R; Carta A; Madeddu S; Caria P; Serreli G; Piras S; Sestito S; Loddo R; Sanna G
Viruses; 2021 Jan; 13(1):. PubMed ID: 33406781
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism of L-SP40 peptide and in vivo efficacy against EV-A71 in neonatal mice.
Lalani S; Tan SH; Tan KO; Lim HX; Ong KC; Wong KT; Poh CL
Life Sci; 2021 Dec; 287():120097. PubMed ID: 34715144
[TBL] [Abstract][Full Text] [Related]
14. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.
Mao Q; Wang Y; Bian L; Xu M; Liang Z
Emerg Microbes Infect; 2016 Jul; 5(7):e75. PubMed ID: 27436364
[TBL] [Abstract][Full Text] [Related]
15. VP1 codon deoptimization and high-fidelity substitutions in 3D polymerase as potential vaccine strategies for eliciting immune responses against enterovirus A71.
Hsieh W-S; Chao C-H; Shen C-Y; Cheng D; Huang S-W; Wang Y-F; Chen C-C; Chen S-H; Hsu L-J; Wang J-R
J Virol; 2024 Jan; 98(1):e0155823. PubMed ID: 38174926
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo studies of a potent capsid-binding inhibitor of enterovirus 71.
Ho JY; Chern JH; Hsieh CF; Liu ST; Liu CJ; Wang YS; Kuo TW; Hsu SJ; Yeh TK; Shih SR; Hsieh PW; Chiu CH; Horng JT
J Antimicrob Chemother; 2016 Jul; 71(7):1922-32. PubMed ID: 27098012
[TBL] [Abstract][Full Text] [Related]
17. Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology.
Yang YT; Chow YH; Hsiao KN; Hu KC; Chiang JR; Wu SC; Chong P; Liu CC
Antiviral Res; 2016 Aug; 132():225-32. PubMed ID: 27387826
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of enterovirus-A71 in children with acute flaccid paralysis in the Philippines.
Apostol LN; Shimizu H; Suzuki A; Umami RN; Jiao MMA; Tandoc A; Saito M; Lupisan S; Oshitani H
BMC Infect Dis; 2019 May; 19(1):370. PubMed ID: 31046684
[TBL] [Abstract][Full Text] [Related]
19. Severity of enterovirus A71 infection in a human SCARB2 knock-in mouse model is dependent on infectious strain and route.
Zhu J; Chen N; Zhou S; Zheng K; Sun L; Zhang Y; Cao L; Zhang X; Xiang Q; Chen Z; Wang C; Fan C; He Q
Emerg Microbes Infect; 2018 Dec; 7(1):205. PubMed ID: 30518755
[TBL] [Abstract][Full Text] [Related]
20. Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell.
Liu Z; Xia S; Wang X; Lan Q; Li P; Xu W; Wang Q; Lu L; Jiang S
ACS Infect Dis; 2020 May; 6(5):882-890. PubMed ID: 32233455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
